JP2022525549A - 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与 - Google Patents

疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与 Download PDF

Info

Publication number
JP2022525549A
JP2022525549A JP2021556556A JP2021556556A JP2022525549A JP 2022525549 A JP2022525549 A JP 2022525549A JP 2021556556 A JP2021556556 A JP 2021556556A JP 2021556556 A JP2021556556 A JP 2021556556A JP 2022525549 A JP2022525549 A JP 2022525549A
Authority
JP
Japan
Prior art keywords
mtor inhibitor
albumin
pharmaceutical composition
nanoparticles
rapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525549A5 (enExample
Inventor
ピー． デサイ，ニール
ホウ，シヘ
Original Assignee
アブラクシス バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス， エルエルシー filed Critical アブラクシス バイオサイエンス， エルエルシー
Publication of JP2022525549A publication Critical patent/JP2022525549A/ja
Publication of JP2022525549A5 publication Critical patent/JP2022525549A5/ja
Priority to JP2025060500A priority Critical patent/JP2025118604A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
    • A61M5/2448—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/284—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2021556556A 2019-03-19 2020-03-18 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与 Pending JP2022525549A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060500A JP2025118604A (ja) 2019-03-19 2025-04-01 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962820842P 2019-03-19 2019-03-19
US201962820838P 2019-03-19 2019-03-19
US62/820,838 2019-03-19
US62/820,842 2019-03-19
PCT/US2020/023366 WO2020191053A1 (en) 2019-03-19 2020-03-18 Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060500A Division JP2025118604A (ja) 2019-03-19 2025-04-01 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与

Publications (2)

Publication Number Publication Date
JP2022525549A true JP2022525549A (ja) 2022-05-17
JP2022525549A5 JP2022525549A5 (enExample) 2023-03-28

Family

ID=72519161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556556A Pending JP2022525549A (ja) 2019-03-19 2020-03-18 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与
JP2025060500A Pending JP2025118604A (ja) 2019-03-19 2025-04-01 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060500A Pending JP2025118604A (ja) 2019-03-19 2025-04-01 疾患の治療のための、ｍＴＯＲ阻害剤およびアルブミンを含むナノ粒子の皮下投与

Country Status (9)

Country Link
US (1) US20220054404A1 (enExample)
EP (1) EP3941551A4 (enExample)
JP (2) JP2022525549A (enExample)
KR (1) KR102936433B1 (enExample)
CN (2) CN120267635A (enExample)
AU (1) AU2020241730B2 (enExample)
CA (1) CA3133988A1 (enExample)
MX (1) MX2021011230A (enExample)
WO (1) WO2020191053A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102936433B1 (ko) 2019-03-19 2026-03-09 아브락시스 바이오사이언스, 엘엘씨 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin
CN114945358A (zh) * 2019-11-11 2022-08-26 阿布拉科斯生物科学有限公司 用于纳米颗粒组合物的生物标记
CN120187414A (zh) * 2022-11-25 2025-06-20 克利凯生物公司 用于靶向炎症性巨噬细胞的纳米平台以及包含其的用于预防或治疗炎症性疾病的组合物
KR20250081554A (ko) * 2023-11-29 2025-06-05 주식회사 에스엔바이오사이언스 시롤리무스 및 알부민을 포함하는 나노입자, 이를 포함하는 피하투여용 약제학적 조성물 및 이의 제조방법

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
JP2010520289A (ja) * 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
JP2016513657A (ja) * 2013-03-14 2016-05-16 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
WO2018064405A1 (en) * 2016-09-28 2018-04-05 Abraxis Bioscience, Llc Methods of treating mitochondrial and metabolic disorders
JP2018521057A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー 類上皮細胞腫瘍を処置する方法
JP2018521058A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
JP2018526334A (ja) * 2015-06-29 2018-09-13 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して血液学的悪性疾患を処置する方法
JP2018527308A (ja) * 2015-06-29 2018-09-20 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物のためのバイオマーカー
JP2021526138A (ja) * 2018-05-22 2021-09-30 アブラクシス バイオサイエンス， エルエルシー 肺高血圧症を処置するための方法および組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684730A (zh) * 2002-09-04 2005-10-19 梅里迪安医学技术公司 药品输送装置
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
US10143700B2 (en) * 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
JP6462859B2 (ja) * 2014-08-18 2019-01-30 ウィンドギャップ メディカル， インコーポレイテッド 携帯型薬剤混合及び送達装置並びに関連の方法
CA2963085C (en) * 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
JP2019513737A (ja) * 2016-04-08 2019-05-30 ギリアード サイエンシーズ， インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
WO2018153984A1 (en) * 2017-02-23 2018-08-30 Universität Bern Mtor inhibitor-corticoid combination therapy for multiple sclerosis
WO2018153969A1 (en) * 2017-02-24 2018-08-30 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with radium-223 salt
MX2021011230A (es) 2019-03-19 2022-03-11 Abraxis Bioscience Llc Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520289A (ja) * 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
JP2016513657A (ja) * 2013-03-14 2016-05-16 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
JP2018521057A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー 類上皮細胞腫瘍を処置する方法
JP2018521058A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
JP2018526334A (ja) * 2015-06-29 2018-09-13 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して血液学的悪性疾患を処置する方法
JP2018527308A (ja) * 2015-06-29 2018-09-20 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物のためのバイオマーカー
WO2018064405A1 (en) * 2016-09-28 2018-04-05 Abraxis Bioscience, Llc Methods of treating mitochondrial and metabolic disorders
JP2021526138A (ja) * 2018-05-22 2021-09-30 アブラクシス バイオサイエンス， エルエルシー 肺高血圧症を処置するための方法および組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102936433B1 (ko) 2019-03-19 2026-03-09 아브락시스 바이오사이언스, 엘엘씨 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여

Also Published As

Publication number Publication date
WO2020191053A1 (en) 2020-09-24
AU2020241730B2 (en) 2025-11-13
KR102936433B1 (ko) 2026-03-09
JP2025118604A (ja) 2025-08-13
EP3941551A1 (en) 2022-01-26
CN120267635A (zh) 2025-07-08
KR20210139367A (ko) 2021-11-22
US20220054404A1 (en) 2022-02-24
AU2020241730A1 (en) 2021-10-28
EP3941551A4 (en) 2023-01-18
CA3133988A1 (en) 2020-09-24
CN113795287A (zh) 2021-12-14
MX2021011230A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
KR102936433B1 (ko) 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여
US10413531B2 (en) Methods of treating bladder cancer
JP7561628B2 (ja) 肺高血圧症を処置するための方法および組成物
KR20180019230A (ko) 나노입자 조성물에 대한 바이오마커
US20210137848A1 (en) Biomarkers for nanoparticle compositions
US20260137665A1 (en) Combination therapies for the treatment of cancer
RU2830582C2 (ru) Способы и композиции для лечения легочной гипертензии
WO2025129108A1 (en) Methods of treating a cancer in an individual
WO2024243413A1 (en) Combination therapy with a mtor inhibitor and a multi-tyrosine kinase inhibitor for treating soft tissue sarcoma
WO2025049962A1 (en) Combination cancer treatments with a composition comprising an mtor pathway inhibitor
WO2024228964A1 (en) Treatments comprising an mtor inhibitor nanoparticle composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250430